摘要
为系统评价感冒清热颗粒治疗小儿风寒感冒的有效性和安全性,该研究系统检索CNKI全文数据库,万方数据库,维普数据库,中国生物医学文献数据库,PubMed医学期刊数据库,EMbase及Cochrane Library 7个中英文数据库,检索感冒清热颗粒治疗小儿风寒感冒的随机对照试验(RCT),对符合纳入标准的文献用Cochrane协作网提供的标准评价文献质量,并用RevMan 5.3软件进行Meta分析。共纳入6篇文献,总样本量492例,试验组246例,对照组246例。Meta分析结果提示,试验组在发热减退时间(d)(MD=-0.38,95%CI[-0.53,-0.23],P<0.01)、临床总有效率(RR=1.25,95%CI[1.15,1.36],P<0.01)、咳嗽缓解时间(d)(MD=-2.75,95%CI[-3.05,-2.46],P<0.01)、鼻塞缓解时间(d)(MD=-1.45,95%CI[-1.69,-1.22],P<0.01)、中医证候积分改善情况(MD=-8.35,95%CI[-9.35,-7.36],P<0.01)方面,均优于对照组(小儿氨酚黄那敏颗粒),差异均有统计学意义。仅2篇文献提及未发生明显不良反应,其余4篇文献均未提及不良反应发生情况。结果表明,感冒清热颗粒治疗小儿风寒感冒在加快退热及缓解临床症状方面疗效优于西药小儿氨酚黄那敏颗粒,但不良反应不明确。鉴于现有文献量不足、质量偏低,其疗效和安全性尚需更多高质量的临床研究进一步证实。
To systematically evaluate the efficacy and safety of Ganmao Qingre Granules in treatment of children with wind-cold syndrome.The study systematically retrieved CNKI,WanFang,VIP,CBM,PubMed,EMbase and Cochrane Library for children cases with wind-cold syndrome treated with RCT.The literature inclusion criteria provided by Cochrane was used to evaluate the litera-ture quality,and Meta-analysis was conducted by RevMan 5.3 software.A total of 6 literatures were included,with a total sample size of 492 cases,including 246 cases in the experimental group and 246 cases in the control group.According to the results of Meta-analysis,the experimental group recorded the hypothermia time(MD=-0.38,95%CI[-0.53,-0.23],P<0.01),the total clinical effective rate(RR=1.25,95%CI[1.15,1.36],P<0.01),the cough relief time(MD=-2.75,95%CI[-3.05,-2.46],P<0.01),the decrease nasal congestion relief time(MD=-1.45,95%CI[-1.69,-1.22],P<0.01),traditional Chinese medicine syndrome score(MD=-8.35,95%CI[-9.35,-7.36],P<0.01),all of them were superior to those of the control group(Aminophenol Huangnamin Granules),with statistically significant differences.Only 2 literatures mentioned no obvious adverse reaction,and the other 4 literatures did not mention any adverse reactions.Based on the results of this study,it was indicated that Ganmao Qingre Granules were effective in the treatment of children with wind-cold syndrome,but with unclear adverse reactions.Due to the insufficient quantity and low quality of included literatures,the efficacy and safety need to be further confirmed by more high-quality clinical studies.
作者
黄燕
吕健
谢雁鸣
孙梦华
HUANG Yan;LYU Jian;XIE Yan-ming;SUN Meng-hua(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Medicine Information Institute,China Academy of Chinese Medical Sciences,Beijing 100700,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2020年第14期3292-3298,共7页
China Journal of Chinese Materia Medica
基金
国家重点研发计划项目(2018YFC1707400,2018YFC1707410)
中央级公益性科研院所基本业务费项目(Z0605)。